Neovascular Age‑Related Macular Degeneration - Symptoms, Causes, Treatment & Prevention

```html

Overview

Neovascular age‑related macular degeneration (nAMD), also called wet AMD, is a progressive eye disease that damages the macula – the central part of the retina responsible for sharp, straight‑ahead vision. In nAMD, abnormal blood vessels grow under the retina and leak fluid or blood, leading to rapid vision loss if untreated.

Who it affects: nAMD most commonly occurs in adults over 60 years of age. While both sexes are affected, women have a slightly higher prevalence because they live longer on average.

Prevalence: According to the World Health Organization (WHO) and the National Eye Institute (NEI), AMD is the leading cause of legal blindness in people over 50 in high‑income countries. Approximately 10–15 % of all AMD cases are the neovascular (wet) form. In the United States, about 1.75 million people have nAMD, and the number is projected to rise to >3 million by 2050 as the population ages (CDC, 2022).

Symptoms

Early nAMD may be asymptomatic, but as the disease progresses the following signs often appear. Prompt recognition is essential because treatment is most effective when started early.

• Blurred or distorted central vision – Straight lines may appear wavy (metamorphopsia).
• Dark or empty spot in the center of vision – Often described as a “hole” or “black spot.”
• Reduced ability to see fine details – Difficulty reading, recognizing faces, or threading a needle.
• Changes in color perception – Colors may look washed out or less vivid.
• Decreased contrast sensitivity – Making it harder to drive at night or in low‑light conditions.
• Rapid vision loss – Unlike the gradual loss seen in dry AMD, wet AMD can cause noticeable decline over weeks.
• Floaters or flashes – Result from bleeding under the retina, though these are less common than in retinal detachment.

If any of these symptoms develop, especially a sudden change in central vision, seek an eye‑care professional immediately.

Causes and Risk Factors

Pathophysiology

In nAMD, the retinal pigment epithelium (RPE) and Bruch’s membrane become damaged, triggering the release of vascular endothelial growth factor (VEGF). VEGF stimulates the growth of fragile, leaky choroidal neovascular membranes (CNV) beneath the macula. Fluid, blood, and scar tissue from these vessels disrupt photoreceptor function, leading to central vision loss.

Key Risk Factors

• Age: Risk rises sharply after age 60; prevalence doubles each decade thereafter.
• Genetics: Variants in the CFH (complement factor H) and ARMS2 genes increase susceptibility (NEI, 2021).
• Smoking: Current smokers have a 2–3‑fold higher risk; former smokers also remain at elevated risk (CDC, 2022).
• Race/Ethnicity: Higher prevalence in White populations; lower in African‑American and Asian groups, though when present the disease can be more aggressive.
• Cardiovascular disease: Hypertension, hyperlipidemia, and atherosclerosis are linked to increased VEGF activity.
• Obesity & diet: High‑glycemic diets and low intake of leafy greens, omega‑3 fatty acids, and lutein/zeaxanthin correlate with higher AMD risk.
• Family history: First‑degree relatives with AMD increase personal risk 3–4 times.
• Excessive sunlight exposure: UV‑blue light may damage the RPE over decades.
• Previous dry AMD: About 10‑15 % of patients with the dry form progress to the wet form each year.

Diagnosis

Diagnosing nAMD requires a thorough eye exam performed by an ophthalmologist or optometrist trained in retinal disease.

Clinical Examination

• Visual acuity test: Determines the level of central vision loss.
• Amsler grid testing: A simple home‑based tool where patients report any distortion, helping to flag early changes.
• Dilated fundus examination: Allows direct visualization of the macula for signs of hemorrhage, exudates, or neovascular membranes.

Imaging & Specialized Tests

• Optical Coherence Tomography (OCT): Non‑invasive cross‑sectional imaging that reveals retinal thickness, fluid pockets, and CNV.
• Fluorescein Angiography (FA): Intravenous dye highlights leaking vessels; essential for mapping CNV extent.
• Indocyanine Green Angiography (ICGA): Better visualizes choroidal vessels and is useful when FA is inconclusive.
• OCT‑Angiography (OCTA): Newer, dye‑free technique that can detect blood flow in neovascular networks.

Diagnosis is usually confirmed when OCT shows sub‑retinal fluid or pigment epithelial detachment together with leakage on FA or OCTA.

Treatment Options

Treatment aims to stop new vessel growth, seal existing leaks, and preserve or improve vision. Early intervention dramatically improves outcomes.

Anti‑VEGF Intravitreal Injections

These are the first‑line therapy for nAMD. Medications are injected directly into the vitreous cavity every 4–12 weeks, depending on disease activity.

• Ranibizumab (Lucentis) – FDA‑approved for nAMD; improves vision in ~30‑40 % of patients.
• Aflibercept (Eylea) – Binds VEGF‑A, VEGF‑B, and placental growth factor; allows extended dosing (every 8 weeks after loading).
• Bevacizumab (Avastin) – An off‑label, cost‑effective option; similar efficacy in many studies (CATT trial).
• Faricimab (Vabysmo) – Dual‑targeted (VEGF and Ang‑2) with potential for 12‑week intervals (FDA 2022).

Typical regimen: three monthly “loading” injections, then a “treat‑and‑extend” or “pro‑re‑nata” schedule based on OCT findings.

Photodynamic Therapy (PDT)

Used less frequently now, PDT combines a light‑activated drug (verteporfin) with a laser to selectively close abnormal vessels. May be combined with anti‑VEGF for certain polypoidal lesions.

Laser Photocoagulation

Traditional thermal laser can seal leaking vessels but carries a risk of damaging surrounding retina; reserved for extrafoveal lesions.

Surgical Options

• Sub‑macular surgery: Rarely performed; involves physically removing the CNV membrane. Outcomes are variable and carry high risk.
• Vitrectomy with anti‑VEGF delivery: Investigational in cases with persistent vitreous hemorrhage.

Lifestyle & Adjunctive Measures

• AREDS2 supplement formula: High‑dose vitamin C, vitamin E, zinc, copper, lutein, and zeaxanthin can slow progression of AMD (Mayo Clinic).
• Smoking cessation: Reduces VEGF activity and overall cardiovascular risk.
• Blood pressure & lipid control: Improves ocular perfusion and may limit CNV development.

Living with Neovascular Age‑Related Macular Degeneration

Managing nAMD is a partnership between the patient, eye‑care team, and support network.

• Regular follow‑up: Most patients need OCT monitoring every 4–8 weeks initially, then spaced out when stable.
• Use of low‑vision aids: Large‑print reading devices, magnifiers, screen‑enhancing software, and adaptive lighting can improve daily functioning.
• Home Amsler grid: Test the grid daily; any distortion should be reported promptly.
• Nutrition: Incorporate leafy greens (spinach, kale), fatty fish (salmon, sardines), and nuts; aim for at least 10 mg lutein + 2 mg zeaxanthin daily.
• Safety adaptations: Ensure good ambient lighting, use contrasting colors on stairs, and keep frequently used items within easy reach.
• Emotional support: Vision loss can cause anxiety or depression. Consider counseling, support groups, or contacting organizations like the Macular Degeneration Association.

Prevention

While genetics cannot be changed, several modifiable factors lower the risk of developing nAMD or its progression.

• Quit smoking: Seek nicotine‑replacement therapy or counseling.
• Adopt a Mediterranean‑style diet: Rich in omega‑3 fatty acids, antioxidants, and low in refined sugars.
• Control cardiovascular health: Manage hypertension, cholesterol, and diabetes.
• Protect eyes from UV/blue light: Wear sunglasses with 100 % UV protection and consider blue‑light filtering lenses for prolonged screen use.
• Regular eye examinations: Adults ≥50 years should have comprehensive dilated exams at least every 1–2 years.
• Consider AREDS2 supplementation if you have intermediate or advanced dry AMD (consult your eye doctor).

Complications

If nAMD is left untreated or inadequately controlled, several serious complications may arise:

• Permanent central vision loss: Scar tissue (sub‑retinal fibrosis) can become irreversible.
• Geographic atrophy: Expansion of dry‑AMD lesions can follow repeated anti‑VEGF injections in some patients.
• Secondary cataract formation: Repeated intra‑ocular injections increase the risk of lens opacities.
• Endophthalmitis: Though rare (<0.05 % per injection), intra‑ocular infection can cause severe vision loss.
• Increased fall risk: Reduced central vision may affect balance and mobility.

When to Seek Emergency Care

---

Sources: Mayo Clinic, Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH) – National Eye Institute, World Health Organization (WHO), Cleveland Clinic, AREDS2 Clinical Trial, CATT Trial, and peer‑reviewed ophthalmology journals (Ophthalmology, JAMA Ophthalmology, Retina).

```